How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Medical Sevofluran Market
- By Product Form: Liquid Sevoflurane, Sevoflurane Vapor
- By Application: General Anesthesia, Pediatric Anesthesia, Outpatient Surgery, Cardiac Surgery, Neurological Surgery
- By End User: Hospitals, Ambulatory Surgical Centers, Clinics, Specialty Surgical Centers
- By Dosage Strength: 1% Sevoflurane, 2% Sevoflurane, 3% Sevoflurane, 4% Sevoflurane
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Liquid Sevoflurane leads By Product Form at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.161 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.169 →
Full report · locked preview
Everything inside the Medical Sevofluran Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Form 2
Application 5
End User 4
Dosage Strength 4
Companies profiled
Baxter International Inc.
AbbVie Inc.
Mylan N.V. (now part of Viatris)
Hikma Pharmaceuticals PLC
Fresenius Kabi AG
Hospira (a Pfizer company)
B. Braun Melsungen AG
Lunan Pharmaceutical Group Co. Ltd.
Jiangsu Hengrui Medicine Co. Ltd.
Macleods Pharmaceuticals Ltd.
Neon Laboratories Ltd.
Glenmark Pharmaceuticals Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Mylan N.V. (now part of Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Hikma Pharmaceuticals PLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Fresenius Kabi AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Hospira (a Pfizer company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →B. Braun Melsungen AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Lunan Pharmaceutical Group Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Jiangsu Hengrui Medicine Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Macleods Pharmaceuticals Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Neon Laboratories Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Glenmark Pharmaceuticals Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sun Pharmaceutical Industries Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Wockhardt Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Cipla Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$1,879M by 2033 · 4.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Liquid Sevoflurane66.0
- Sevoflurane Vapor34.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$451.5M → $598.2M · 3.6%
Europe$314.7M → $409.8M · 3.4%
Asia Pacific$287.3M → $351.6M · 2.6%
Latin America$177.9M → $244.8M · 4.1%
Middle East and Africa$136.8M → $193.0M · 4.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.002026
4.002027
4.012028
4.022029
4.042030
4.052031
4.072032
4.092033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Baxter International Inc.20.7
- AbbVie Inc.17.7
- Mylan N.V. (now part of Viatris)9.6
- Hikma Pharmaceuticals PLC7.1
- Fresenius Kabi AG9.8
- Hospira (a Pfizer company)7.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Form27.9%
Application19.5%
End User16.1%
Dosage Strength36.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.3
- Europe22.8
- Asia Pacific19.6
- Latin America13.6
- Middle East and Africa10.7
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Baxter International Inc. | 98 | 97 | 85 | 94 | 88 | 91 | 92 |
| AbbVie Inc. | 88 | 84 | 68 | 86 | 77 | 69 | 79 |
| Mylan N.V. (now part of Viatris) | 80 | 66 | 66 | 85 | 86 | 80 | 77 |
| Hikma Pharmaceuticals PLC | 76 | 58 | 60 | 60 | 79 | 81 | 69 |
| Fresenius Kabi AG | 53 | 74 | 73 | 67 | 67 | 66 | 67 |
| Hospira (a Pfizer company) | 64 | 58 | 54 | 62 | 51 | 51 | 57 |
| B. Braun Melsungen AG | 63 | 62 | 47 | 59 | 50 | 50 | 55 |
| Lunan Pharmaceutical Group Co. Ltd. | 46 | 37 | 35 | 55 | 60 | 57 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Baxter International Inc.
- AbbVie Inc.
- Mylan N.V. (now part of Viatris)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Baxter International Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| AbbVie Inc. | ✓ | ◐ | − | ◐ | ◐ | ◐ |
| Mylan N.V. (now part of Viatris) | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Hikma Pharmaceuticals PLC | ◐ | − | − | ◐ | ✓ | ✓ |
| Fresenius Kabi AG | − | ✓ | ◐ | − | ◐ | ◐ |
| Hospira (a Pfizer company) | ◐ | − | − | − | − | − |
| B. Braun Melsungen AG | ✓ | − | ◐ | ◐ | ◐ | ◐ |
| Lunan Pharmaceutical Group Co. Ltd. | ◐ | − | − | ◐ | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Baxter International Inc.92
2AbbVie Inc.79
3Mylan N.V. (now part of Viatris)77
4Hikma Pharmaceuticals PLC69
5Fresenius Kabi AG67
6Hospira (a Pfizer company)57
7B. Braun Melsungen AG55
8Lunan Pharmaceutical Group Co. Ltd.48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Baxter International Inc.AbbVie Inc.
Challenger3
Strong scale, closing on the leaders.
Mylan N.V. (now part of Viatris)Hikma Pharmaceuticals PLCFresenius Kabi AG
Contender1
Focused players with pockets of strength.
Hospira (a Pfizer company)
Niche2
Specialists in a single segment or region.
B. Braun Melsungen AGLunan Pharmaceutical Group Co. Ltd.
Go-to-market strategy
Land Product Form in North America, then scale across Medical Sevofluran Market — a $216M beachhead inside a $3.08B market.
Beachhead (SOM)$216Mobtainable near-term
Serviceable (SAM)$1.26Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Liquid Sevoflurane
Best fit — highest urgency & budget in Product Form.
Economic buyer77 fit
Sevoflurane Vapor
Strong fit — clear ROI and a fast path to value.
End user66 fit
Enterprise buyers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Form in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel28%
Digital / self-serve17%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Form leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Medical Sevofluran Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation12%
Closed-won6%
$15.0KCAC
$60KLTV
4.0:1LTV : CAC
< 4 moCAC payback
Investment thesis
Medical Sevofluran Market is a high-growth opportunity — $10.8B by 2033, compounding at 11.4%.
TAM · 2025$4.55Btoday
TAM · 2033$10.8Bforecast
CAGR11.4%2027–2033
Cumulative$65.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.8BTotal addressable market
SAM$4.01BServiceable available market
SOM$853MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.4% CAGR
Demand compounds through 2033, outpacing GDP across Product Form.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Form moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.8BLarge & growingTAM by 2033 at 11.4% CAGR
$4.01BServiceable nowreachable with today’s model
$853MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.44BBear7.4% CAGR
$10.8BBase11.4% CAGR
$13.9BBull15.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Medical Sevofluran Market — a $9.09B market by 2033. Plan: grow share from 7.2% to 14.1%.
Market size · 2033$9.09Btotal addressable
Market CAGR9.2%2027–2033
Target share14.1%from 7.2% today
Revenue ambition$1.28Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.2% | 14.1% | Ahead |
| Revenue | $693M | $1.28B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.8% | 41.8% | At risk |
| Customer retention | 85.7% | 95.1% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Form
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Form share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $128M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Form leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentAhead
Sales deck · value proposition
Win the Medical Sevofluran Market conversation — a $3.79B market you can size, segment and defend in minutes.
Market size · 2033$3.79Btotal opportunity
Growth6.2%CAGR to 2033
Addressable buyers985+accounts in scope
Typical ROI4.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Form
Goal Grow share in Product Form
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.7×return on cost, year one
< 3 mopayback period
$64K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Baxter International Inc.AbbVie Inc.Mylan N.V. (now part of Viatris)Hikma Pharmaceuticals PLCFresenius Kabi AGHospira (a Pfizer company)B. Braun Melsungen AGLunan Pharmaceutical Group Co. Ltd.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Medical Sevofluran Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Medical Sevofluran Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Cephalexine Market
Market size, share, segmentation and regional forecast.
$9.3B by 2031 · 6.51% CAGR
View reportScar Dressings Market
Market size, share, segmentation and regional forecast.
$4.1B by 2033 · 9.96% CAGR
View reportAge-relatedMacularDegeneration (ARMD) Drugs Market
Market size, share, segmentation and regional forecast.
$9.1B by 2032 · 5.21% CAGR
View reportAerospace and Life Science TIC Market
Market size, share, segmentation and regional forecast.
$9.5B by 2031 · 8.13% CAGR
View reportAerobic Culturing Bottle Market
Market size, share, segmentation and regional forecast.
$13.1B by 2032 · 7.68% CAGR
View reportRemote Patient Monitoring Systems Market
Market size, share, segmentation and regional forecast.
$13.8B by 2032 · 5.37% CAGR
View reportAdvanced Prosthetics and Exoskeletons Market
Market size, share, segmentation and regional forecast.
$3.9B by 2032 · 5.98% CAGR
View reportAdvanced Animal Ventilators Market
Market size, share, segmentation and regional forecast.
$7.1B by 2031 · 6.06% CAGR
View reportClinical Decision Support System (CDSS) Market
Market size, share, segmentation and regional forecast.
$9.5B by 2033 · 4.04% CAGR
View reportAdjunctive Haemostats Market
Market size, share, segmentation and regional forecast.
$10.8B by 2032 · 8.01% CAGR
View reportAdditives for Inkjet Inks Market
Market size, share, segmentation and regional forecast.
$10.4B by 2032 · 4.30% CAGR
View reportAcyclovir for Injection Market
Market size, share, segmentation and regional forecast.
$13.2B by 2033 · 3.35% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.